FREE Account Opening + No Clearing Fees

Tatva Chintan IPO review (Apply)

Review By Dilip Davda on July 13, 2021

•    TCPCL is a niche global player in specialty chemicals with SDAs in centre stage.
•    It has posted growth in its top and bottom lines for the past three years.
•    The issue is priced reasonably compared to listed peers.
•    Globally renowned client list with long term relations.

Tatava Chintan Pharma Chem Ltd. (TCPCL) is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure-directing agents ('SDAs'), phase transfer catalysts ('PTCs'), electrolyte salts for supercapacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals ('PASC'). The Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second-largest position globally. (Source: F&S Report)

In addition, TCPCL is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. (Source: F&S Report) As a manufacturer of specialty chemicals, it focuses on the application of its products which form a key ingredient to customers' manufacturing and industrial processes. For instance, SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.

The company continuously strives to improve processes and infrastructure to help reduce its impact on the environment and have accordingly, undertaken various 'green' chemistry processes such as electrolysis. Considering the wide application of its products, it serves customers across various industries, including the automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries.

Apart from its customers in India, the company also exports products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK. During the Fiscals ended March 31, 2019, 2020, and 2021, exports of products amounted to Rs.  143.52 cr., Rs. 202.02 cr. and Rs. 211.99 cr. which accounted for 69.57%, 76.74%, and 70.58%, of its revenue from operations, respectively. As of March 31, 2021, its portfolio had 154 products in four categories i.e. SDAs, PTCs, Electrolyte Salts and Pharma/Agri intermediates.

TCPCL's customers include Merck, Bayer AG, Asian Paints Ltd., Ipox Chemicals KFT, Laurus Labs Ltd., Tosoh Asia Pte. Ltd., SRF Limited, Navin Fluorine International Limited, Oriental Aromatics Ltd., Atul Limited, Otsuka Chemical (I) Pvt Ltd., Meghmani Organics Limited, Divi's Laboratories Limited, Hawks Chemical Company Limited, Firmenich Aromatics Prod. (I) Pvt. Ltd., Jiangsu Guotai Super Power New Materials Co., Ltd. and Jade Chem Co. Ltd.

To part finance its need for funding capital expenditure for expansion of its Dahej facility (Rs. 147.10 cr.), up-gradation of its R & D facility (Rs. 23.97 cr.) and general corpus funds, TCPCL is coming out with a maiden IPO of Rs. 500 cr. comprising of fresh equity issue worth Rs. 225 cr. (2077556 shares) and an offer for sale (OFS) of Rs. 275 cr. (2539244 shares). The company will be issuing approx. 4616800 shares of Rs. 10 each on the basis of the upper price band. TCPCL has fixed a price band of Rs. 1073 - Rs. 1083 per share having a face value of Rs. 10. The issue opens for subscription on July 16, 2021, and will close on July 20, 2021. Minimum application is to be made for 13 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE and NSE. The issue constitutes 20.83 % of the post issue paid-up capital of TCPCL. The company has allocated an IPO quota of 50% for QIBs, 15% for HNIs and 35% for retail investors.

Book Running Lead Managers (BRLMs) to this issue are ICICI Securities Ltd. and JM Financial Ltd. while Link Intime India Pvt. Ltd. is the registrar to the issue.

TCPCL's entire equity is issued at par so far. It has also issued bonus shares in the ratio of 1 for 2 in March 2001, 1 for 1 in March 2006, 12 for 10 in March 2009 and 1.5 for 1 in March 2021.

The average cost of acquisition of shares by the promoters/selling stakeholders is Rs. 0.91, Rs. 1.11, Rs. 1.59, Rs. 1.65, Rs. 2.49, Rs. 2.69, Rs. 2.87, Rs. 3.06 and Rs. 4.00 per share. Post-IPO, TCPCL's current paid-up equity capital of Rs. 20.09 cr. will stand enhanced to Rs. 22.17 cr. Based on the upper price band, the company is looking for a market cap of Rs. 2400.48 cr.

On the financial performance front, TCPCL has reported turnover/net profits of Rs. 206.80 cr. / Rs. 20.54 cr. (FY19), Rs. 264.62 cr. / Rs. 37.79 cr. (FY20) and Rs. 306.29 cr. / Rs. 52.26 cr. (FY21). Thus it has posted growth in top and bottom lines for the past three fiscals. It has posted a CAGR of 21.70% in top lines and a CAGR of 59.50% in bottom lines. Its debt-equity ratio stood at 0.54 as of March 31, 2021.

For the last three fiscals, TCPCL has posted an average EPS of Rs. 20.99 and an average RoNW of 30.75%. The issue is priced at a P/BV of 13.11 based on its NAV of Rs. 82.62 as of March 31, 2021, and at a P/BV of 6.14 based on its post-IPO NAV of Rs. 176.39 (based on the cap price).

If we attribute FY21 earnings on fully diluted post issue equity, then the asking price is at a P/E of around 45.95 and thus the issue is reasonably priced as the industry composite is around 56 as per RHP data.

As per the offer documents, TCPCL has shown Aarti Ind., Navin Fluorine, Alkyl Amines, Vinati Organics and Fine Organics as its listed peers. They are currently trading at a P/E of 60.43, 75.53, 65.61, 73.36 and 80.79 respectively (as of July 13, 2021). However, they are not truly comparable on an apple to apple basis.  

In the last three fiscals, TCPCL has paid a dividend of 50% (on pre-bonus equity) for FY21 only. It will adopt a prudent dividend policy post listing based on its financial performance and future prospects.

The two BRLMs associated with the offer have handled 33 public issues in the past three years, out of which 11 issues closed below the issue price on the listing date.

Conclusion / Investment Strategy

The company is in a fast forward mode and the issue is reasonably priced. The green chemical industry is fancied by investors across the board. Investment may be considered for short to long term rewards.

Reviewer recommends Subscribing to the issue.

Review By Dilip Davda on July 13, 2021

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. My reviews do not cover GMP market and operators game plans. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Tatva Chintan Pharma IPO FAQs

  1. 1. Why Tatva Chintan Pharma IPO?

    The initial public offer (IPO) of Tatva Chintan Pharma Chem Ltd offers an early investment opportunity in Tatva Chintan Pharma Chem Ltd. A stock market investor can buy Tatva Chintan Pharma IPO shares by applying in IPO before Tatva Chintan Pharma Chem Ltd shares get listed at the stock exchanges. An investor could invest in Tatva Chintan Pharma IPO for short term listing gain or a long term.

  2. 3. Tatva Chintan Pharma IPO what should investors do?

    Tatva Chintan Pharma IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Tatva Chintan Pharma IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  3. 4. Is Tatva Chintan Pharma IPO good?

    Our recommendation for Tatva Chintan Pharma IPO is to subscribe.

  4. 5. Is Tatva Chintan Pharma IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe to the Tatva Chintan Pharma IPO.

  5. 6. When will Tatva Chintan Pharma IPO allotment status?

    The Tatva Chintan Pharma IPO allotment status will be available on or around July 26, 2021. The allotted shares will be credited in demat account by July 28, 2021. Visit Tatva Chintan Pharma IPO allotment status to check.

  6. 7. When will Tatva Chintan Pharma IPO list?

    The Tatva Chintan Pharma IPO will list on Thursday, July 29, 2021, at BSE, NSE.


4. Rajendra Nawal     Link|July 27, 2021 11:06:34 AM
Link in time opened for Tatva for a while and closed again!!!!!!!!
4.1. Travel mood     Link|July 27, 2021 1:26:01 PM
Now it is working
3. Rajendra Nawal     Link|July 27, 2021 11:06:11 AM
Link in time opened for Tatva for a while and closed again!!!!!!!!
2. Rajendra Nawal     Link|July 27, 2021 11:06:02 AM
Link in time opened for Tatva for a while and closed again!!!!!!!!
1. CP patel     Link|July 26, 2021 8:32:12 PM
Any Allotment link